Oral food challenge reactions appear more common in patients on dupilumab, despite the biologic lowering food-specific IgE levels, according to a Medscape report on new findings presented to the allergy and dermatology community.

The observation cuts against the expected pattern. Dupilumab, the IL-4 receptor alpha antagonist approved for atopic dermatitis and other type 2 inflammatory conditions, reliably suppresses the IgE axis. Clinicians have therefore assumed that food allergy reactivity in treated patients would track downward with the immunologic marker. The new data suggest the opposite behavior during supervised oral food challenges.

What did the analysis find?

Researchers compared oral food challenge outcomes in dupilumab-treated patients against untreated controls and found that clinical reactions during challenge occurred more frequently in the dupilumab group — even though those same patients carried lower food-specific IgE levels than their untreated counterparts.

The discordance matters because oral food challenge remains the reference standard for diagnosing food allergy. Allergists and dermatologists who manage children and adults with moderate-to-severe atopic dermatitis increasingly co-manage IgE-mediated food allergy, and many of those patients now receive dupilumab.

The finding implies that laboratory thresholds clinicians use to predict challenge outcome — food-specific IgE, and by extension skin prick testing — may lose predictive value once a patient starts the biologic. A lower IgE number on dupilumab may not mean a safer challenge.

Why does this matter for dermatology practice?

Atopic dermatitis and food allergy overlap substantially, particularly in pediatric cohorts. Dermatologists who initiate dupilumab in these patients, or who counsel families about dietary restriction, may need to revisit assumptions baked into older guidance:

• Food-specific IgE values measured on dupilumab may underestimate residual allergic reactivity.
• Supervised oral food challenge — not serology alone — should drive decisions about reintroducing allergenic foods in treated patients.
• Clinicians should not interpret a falling IgE level during dupilumab therapy as evidence of food allergy resolution.

How should clinicians interpret the IgE disconnect?

Type 2 blockade by dupilumab suppresses IL-4 and IL-13 signaling, which drives down IgE production. Clinical reactivity to food allergens, however, depends on effector pathways — mast cell and basophil activation through tissue-bound IgE and other mechanisms — that may not decline in parallel with circulating antibody levels.

A dissociation between serologic markers and clinical challenge outcomes would fit that mechanism: the measurable IgE falls, but enough functional effector capacity persists at the tissue level to produce reactions when allergen is administered under supervision.

The Medscape report presents the finding as an observation from challenge data rather than a definitive mechanism, and clinicians should treat it as a signal warranting caution rather than a change in dupilumab's established efficacy or safety profile in atopic dermatitis.

What comes next?

Confirmatory work will need larger controlled challenge cohorts to quantify the reaction rate difference on versus off dupilumab and to determine whether the effect persists across allergens and age groups. Until then, clinicians supervising oral food challenges in dupilumab-treated patients should weigh the possibility that reactions occur more often than serology predicts.